Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Announcements
                          • Events
                            • Newsletter
                              • Press release on our reports
                                • Press photos
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News
                                  • Announcements

                                  Announcements

                                  Fotoleiste-1b

                                   

                                  Current & archive

                                  Adobestock-329115246-von-mike-fouque-klein19
                                  ©stock.adobe.com

                                  Covid-19: HSS/ Horizon Scanning Living Document (v22 June/July2022)

                                  The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

                                  All work steps are conducted in close international (European) cooperation.

                                  Publications: 

                                  • Policy Brief No. 002: http://eprints.aihta.at/1234/

                                  Contact: Claudia Wild

                                  More...

                                  2166
                                  ©stock.adobe.com

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce our two new HSO Fact Sheets.

                                  Fact Sheet No. 98 (June 2022) 
                                  Selinexor (Nexpovio®) in and dexamethasone for the treatment of multiple myeloma (MM)

                                  Fact Sheet No. 99 (June 2022) 
                                  Pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of stage IIb IIc III melanoma

                                  More...

                                  Fotolia-115223963-von-jag-cz3
                                  ©stock.adobe.com

                                  ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022

                                  This report is an update of a previous Horizon Scanning report from 2020, which identified 32 ATMPs. Since August 2020, six of these new ATMPs have been approved by the EMA and five more will be decided by 2023. According to market analyses, 535 ATMPs will be investigated in phase 1 to 3 in 2022, with a further 1,451 in preclinical stages. Coagulation factor VIII (haemophilia A) remains the most common target for non-oncology indications and coagulation factor IX (haemophilia B) has risen to become the second most common indication.

                                  To answer the questions, a systematic search of trial registries was conducted to identify gene therapies and ATMPs in development, followed by extraction of data on identified ongoing clinical trials (limited to phase 2/3 and 3), complemented by a search of the EMA database of medicines under assessment to identify those therapies that are close to approval. Published information on the products and the current development/regulatory status was then collected and subsequently converted into short "vignettes".

                                  Publication: Policy Brief No. 006b: https://eprints.aihta.at/1383

                                  Contact: Ozren Sehic

                                  More...

                                  2165
                                  ©stock.adobe.com

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce our six new HSO Fact Sheets.

                                  Fact Sheet No. 92 (May 2022)
                                  Mosunetuzumab (Lunsumio®) Follicular lymphoma

                                  Fact Sheet No. 93 (May 2022)
                                  Capmatinib (Tabrecta®) NSCLC 

                                  Fact Sheet No. 94 (May 2022)
                                  Pembrolizumab (Keytruda®) TNBC

                                  Fact Sheet No. 95 (May 2022)
                                  Selpercatinib (Retsevmo®) NSCLC

                                  Fact Sheet No. 96 (May 2022)
                                  Atezolizumab (Tecentriq®) NSCLC

                                  Fact Sheet No. 97 (May 2022)
                                  Axicabtagene ciloleucel (Yescarta®) Follicular lymphoma

                                  More...

                                  Adobestock-329115246-von-mike-fouque-klein18
                                  ©stock.adobe.com

                                  Covid-19: HSS/ Horizon Scanning Living Document (v21 April/ May 2022)

                                  The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

                                  All work steps are conducted in close international (European) cooperation.

                                  Publications: 

                                  • Policy Brief No. 002: http://eprints.aihta.at/1234/

                                  Contact: Claudia Wild

                                  More...

                                  2164
                                  ©stock.adobe.com

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce our six new HSO Fact Sheets.

                                  Fact Sheet No. 86 (April 2022) 
                                  Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)

                                  Fact Sheet No. 87 (April 2022)
                                  Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)

                                  Fact Sheet No. 88 (April 2022)
                                  Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy

                                  Fact Sheet No. 89 (April 2022) 
                                  Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)

                                  Fact Sheet No. 90 (April 2022) 
                                  Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer

                                  Fact Sheet No. 91 (April 2022) 
                                  Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer

                                  More...

                                  Adobestock-139482561-von-jpmotion2d1
                                  ©stock.adobe.com

                                  Telemonitoring in Austrian diabetes care: A systematic analysis of evaluation methodologies

                                  The treatment of diabetes mellitus is individually tailored to achieve freedom from symptoms and avoid acute complications and serious secondary diseases. Telemedical diabetes care programs can be supported by digital health applications and may be beneficial to improve diabetes care. This report provides an overview of Austrian telemedicine activities and a systematic review of evaluation methods and evidence of potential health care effects.

                                  Publication: HTA Project Report No. 143: https://eprints.aihta.at/1370/

                                  Contact: Gregor Goetz

                                  More...

                                  Adobestock-139196320-von-serhiibobyk
                                  ©stock.adobe.com

                                  Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries

                                  Prenatal screening and diagnostic tests include First Trimester Screening/Combined Test, non-invasive prenatal test (NIPT), invasive (diagnostic) tests and ultrasound screening for fetal anomalies in the second trimester. Whether and in what form these tests are offered and financed to pregnant women varies considerably between countries. This policy brief provides an overview of country strategies for integrating the tests into antenatal care and their (public) financing in 6 selected European countries (DE, CH, NL, UK, NO, IT).

                                  Publication: Policy Brief No. 12: https://eprints.aihta.at/1369/

                                  Contact: Inanna Reinsperger

                                  More...

                                  Fotolia-115223963-von-jag-cz1
                                  ©stock.adobe.com

                                  CAR-T Cell-Therapies in Development, Update 2022

                                  CAR-T cell-therapies are commonly indicated as „transformative“ therapies referring to the huge expectations associated with them since their market approval in 2017 (USA) and 2018 (Europe). Due to the hope, but also the enormous prices a horizon scanning (HS) document was first published in 2020 to support budget planning in hospitals. In 2020 13 CAR-T cell-therapies in advanced stages were identified. Of these, in addition to Yescarta® and Kymriah®, that were already approved at that time, three further therapies have since been approved by the European Medicines Agency (EMA) between 8/ 2020 and 03/2022: Tecartus® (2020), Abcema® (2021) and Breyanzi® (2022).

                                  This HS document updates the earlier report by surveying the status of the ten therapies already described in 2020 and adding additional therapies that have since then reached a later phase of clinical testing. Within the next year 2023 one new CAR-T cell-Therapy for multiple myeloma will eventually be approved, but further development can be expected with the extension of the approved CAR-T cell-therapies towards earlier lines of therapy and new indications.

                                  Publication: Policy Brief No. 6a, 1. Update: https://eprints.aihta.at/1368

                                  Contakt: Ozren Sehic

                                  More...

                                  2163
                                  ©stock.adobe.com

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce our seven new HSO Fact Sheets.

                                  Fact Sheet No. 79 (March 2022)
                                  Tebentafusp (Kimmtrak®) bei Uveal melanoma

                                  Fact Sheet No. 80 (March 2022)
                                  Relugolix (Orgovyx®) bei Prostate Cancer

                                  Fact Sheet No. 81 (March 2022)
                                  Nivolumab (Opdivo®) bei MIUC

                                  Fact Sheet No. 82 (March 2022)
                                  Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC

                                  Fact Sheet No. 83 (March 2022)
                                  Nivolumab (Opdivo®) + chemotherapy bei OSCC

                                  Fact Sheet No. 84 (March 2022)
                                  Abemaciclib (Verzenios®) bei early breast cancer

                                  Fact Sheet No. 85 (March 2022)
                                  Enfortumab vedotin (Padcev®) Urothelial cancer

                                  More...

                                  « < ... 3 4 5 6 7 ... > »
                                  Displaying results 41 to 50.
                                  • News
                                    • Announcements
                                      • Events
                                        • Newsletter
                                          • Press release on our reports
                                            • Press photos
                                            • About us
                                              • Evaluation
                                                • History
                                                  • Methods
                                                    • Team
                                                      • Shareholder & organization chart
                                                        • Stakeholder involvement
                                                          • Press clippings
                                                          • Research areas
                                                            • Oncology
                                                              • High tech medicine
                                                                • Rehabilitation and occupational therapy
                                                                  • Prevention and screening
                                                                    • Psychological & psychiatric interventions
                                                                      • Health economics
                                                                        • European collaboration
                                                                          • HTA-methods & steering instruments
                                                                            • Complementary medicine
                                                                            • Research Projects
                                                                              • Synopsis of current research projects
                                                                                • Synopsis of completed research projects
                                                                                  • HTA-Information Service Rapid Reviews
                                                                                    • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                      • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                        • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                          • Evaluation of individual medical procedures - Reports
                                                                                            • All projects in an overview
                                                                                            • Publications
                                                                                              • Repository
                                                                                                • HTA-Newsletter
                                                                                                  • Annual Reports
                                                                                                  • Search
                                                                                                    Netzwerk
                                                                                                    • Eunethta
                                                                                                    • Ebm
                                                                                                    • Inahta
                                                                                                    • Dexhelpp
                                                                                                    Shareholder
                                                                                                    • Bmfg
                                                                                                    • Sv
                                                                                                    • Wgfond
                                                                                                    • Noe
                                                                                                    • Ooghfond
                                                                                                    • Ghls
                                                                                                    • Tirol
                                                                                                    • Vorarlberg
                                                                                                    • Kghfond
                                                                                                    • Ghpf
                                                                                                    • Burgef
                                                                                                    • Contact
                                                                                                      • Imprint
                                                                                                        • Privacy Notice
                                                                                                          • Newsletter
                                                                                                            • Sitemap
                                                                                                              © 2023 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                              • Log in